Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AMY-101 by Amyndas Pharmaceuticals for Glomerulonephritis: Likelihood of Approval
AMY-101 is under clinical development by Amyndas Pharmaceuticals and currently in Phase I for Glomerulonephritis. According to GlobalData, Phase I...